ACURA PHARMACEUTICALS INC
Acura Pharmaceuticals develops technologies and products for safe medication use. They offer Oxaydo tablets for pain management and Nexafed products for nasal decongestants. The company collaborates with Egalet to manufacture and commercialize Oxaydo worldwide. Acura also has an agreement with Abuse Deterrent Pharma to develop LTX-03, a LIMITx technology tablet.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 74.8% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Deteriorating fundamentals over the last year: return on assets down 32.6 points and asset turnover down 11.6%.
- ROIC of 0.0% trails 84% of its 55 Drug Manufacturers - Specialty & Generic peers (median 11.0%).
Key Financial Data